Chanelle’s global innovation award

Galway’s Chanelle Group has won the prestigious ‘Pharma Project of the Year’ Award at Ireland’s Pharma Industry Awards 2016.

The Award was in recognition of the development by Chanelle of a super generic drug treatment called Rheumocam® Granules, which treats musculo-skeletal disorders in horses such as arthritis.

Chanelle spent five years developing Rheumocam in granule format which is a world first for the equine market. The product is deemed a ‘super generic’ as it is a new granule formulation of an existing generic drug, Meloxicam.

Manufacturing the medicine as a granule rather than in liquid format means the horse does not have to be handled – the treatment is sprinkled on the animal’s food, making it easier to administer.  There is no need for injections or for dosage measurement and innovations such as adding apple flavouring makes it highly palatable for the horse.

“The development of Rheumocam Granules is a true example of Chanelle’s innovation, enabling us to compete on the global stage”, said Michael Burke, founder and managing director of the Chanelle Group.